New inflation-linked drug rebates go into effect on Saturday
Beginning tomorrow, biopharma companies can be charged rebates for any new drug price increases rising faster than the rate of inflation.
The new rebates are part of the newly signed Inflation Reduction Act, which introduces this new requirement that manufacturers pay rebates to Medicare for Part D drugs whose price increases exceed inflation, and in January 2023, the same will occur with Part B drugs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters